

F. No. ND/CT/25/000064
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-11 0002

To

M/s Pfizer Limited,
The Capital, 1802/1901, Plot No. C-70,
G Block, Bandra Kurla Complex,
Bandra (East), Mumbai, Maharashtra (India)- 400051

Subject: Grant of permission to conduct Phase-IV Clinical trial of drug Rimegepant Orally Disintegrating Tablets 75 mg vide protocol titled "An Open-Label Multicenter Study to Evaluate the Safety and Tolerability of Rimegepant 75mg ODT for Acute Treatment of Migraine in Adult Participants in India With Previous Insufficient Response to Triptans" (protocol number C4951088, Protocol amendment 1 dated 16.12.2025)- regarding.

Sir,

With reference to your application no. **ND/CT04/FF/2025/50433** dated **25.06.2025**, please find enclosed herewith the permission in **Form CT-06 vide no. ND/CT /19/2026** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully
RAJEEV SINGH Digitally signed by RAJEEV SINGH RAGHUVANSHI
RAGHUVANSHI Date: 2026.05.07 10:41:19 +05'30'
(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

Conditions of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the

Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

FORM CT-06*(See rules 22, 25, 26, 29 and 30)***PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG****CT Permission No: ND/CT /19/2026**

The Central Licensing Authority hereby permits, **M/s Pfizer Limited, The Capital 1802/1901 Plot No. C-70 G Block Bandra-Kurla Complex Bandra (E) Mumbai City (India) - 400051 Telephone No.: 022-66932176 FAX: 022-26540274 E-Mail: ABHINAV.SHRIVASTAVA@PFIZER.COM** to conduct clinical trial of the new drug as per **Protocol no. C4951088, Protocol amendment 1 dated 16.12.2025**) in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

Names of the new drug or investigational new drug:		Rimegepant Oral disintegrating tablets (ODT) 75 mg	
Therapeutic class:		Calcitonin gene related peptide antagonist	
Dosage form:		Oral Disintegrating Tablets	
Composition:		Each orally disintegrating tablet contains Rimegepant 75mg (equivalent to 85.67 mg Rimegepant sulfate) Excipients: Gelatin, Mannitol (E421), Mint Flavour, Sucralose	
Indications:		For Acute treatment of migraine with or without aura in adults with a previous insufficient response to triptans.	
Details of clinical trial sites-			
Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee	Name/Registration Number
1.	Dr. Sumit Singh Artemis Hospital, Sector - 51, Gurgaon-122001, Haryana, India	Artemis Health Sciences Institutional Ethics committee, Artemis Hospital, Sector 51 Gurgaon 122001, Haryana.	ECR/53/Inst/HR/2013/RR-24
2	Dr. Amit Yeole 1.Chopda Medicare and Research Centre Pvt. Ltd., 3/5, Patil Lane No. 1, Laxmi Nagar, Near K. B. H. Vidyalaya, Canada Corner, Nashik-422005, Maharashtra, India 2. Chopda Medicare & Research Centre Pvt. Ltd; Magnum Heart Institute, Clinical Research Department, Flat No. 10, Laxmanrekha Apartment, Behind Magnum Heart Institute, Patil Lane No. 1, Canada Corner, Nashik-422005, Maharashtra, India.	Magna-Care Ethics Committee, Chopda Medicare and Research Centre Pvt. Ltd., Magnum Heart Institute, Canada Corner, Nashik, Maharashtra -422005, India	ECR/79/Inst/MH/2013/RR-24

3	Dr. Shankara Nellikunja Mallikatta Neuro Centre Opp. Mallikatta Circle, Kadri, Mangalore- 575002, Karnataka, India	Mangala Institutional Ethics Committee Mangala Hospital & Mangala Kidney Foundation, Vajra Hills, Kadri Road, Mangaluru-575003, Dakshina Kannada, Karnataka, India. ECR/567/Inst/KA/2014/RR-24
4	Dr. Anup Thacker Medanta Hospital Lucknow, Sector - A, Pocket-1, Sushant Golf City, Amar Shaheed Path, Lucknow- 226030, Uttar Pradesh, India	Institutional Ethics Committee Medanta Lucknow, UG floor, Sector - A, Pocket-1, Sushant Golf City, Amar Shaheed Path, Lucknow-226030, Uttar Pradesh, India ECR/1529/INST/UP/2021
5	Dr. Biman Kanti Ray Bangur Institute of Neurosciences, IPGME&R- SSKM Hospital, 244, AJC Bose Road, Kolkata -700020, West Bengal, India.	IPGME&R Research Oversight Committee C/O Office of The Dean of Student Affairs Academic Building (Ground Floor), IPGME&R and SSKM Hospital, 244, AJC Bose Road, Kolkata - 700020, West Bengal, India. ECR/35/Inst/WB/2013/RR-24
6	Dr. Balapradeep Boyidapu Visakha Institute of Medical Sciences, Hanumanthavaka, Chinnagadhili, Visakhapatnam- 530040, Andhra Pradesh, India.	Visakha Institute of Medical Sciences, S. No. 97/2, Hanumanthavaka, chinnagadhili, Visakhapatnam530040, Andhra Pradesh, India. ECR/1421/Inst/AP/2020/RR-25
7	Dr. Anshu Rohtagi, Sir Ganga Ram Hospital, SGRH Marg, Rajinder Nagar, New Delhi- 110060, India	Sir Ganga Ram Hospital Ethics Committee, Room No 1643, 6th floor, Casualty Building, Rajinder Nagar, New Delhi-110060, India. ECR/20/Inst/DL/2013/RR-24
8	Dr Santhosh Kumar D V BGS Global Institute of Medical Sciences, No. 67, BGS Health and Education City, Uttarahalli Road, Kengeri, Bangalore-560060, Karnataka, India	Institutional Ethics Committee, BGS Global Institute of Medical Sciences, No. 67, BGS Health and Education City, Uttarahalli Road, Kengeri, Bangalore-560060, Karnataka, India. ECR/1307/Inst/KA/2019/RR-24
9	Yogesh Patidar Bhaktivedanta Hospital & Research Institute, Srishti Complex, Bhaktivedanta Swami Marg, Mira Road (East), Thane - 401107, Maharashtra, India	Bhaktivedanta Hospital Ethics Committee, 3rd Floor, Bhaktivedanta HEC Office, Bhaktivedanta Hospital & Research Institute, Srishti Complex, Bhaktivedanta Swami Marg, Mira Road (E), Thane - 401107, Maharashtra, India. ECR/396/Inst/MH/2013/RR-24

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

RAJEEV SINGH
RAGHUVANSHI

Digitally signed by RAJEEV
SINGH RAGHUVANSHI
Date: 2026.05.07 10:41:07
+05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority
Stamp

New Delhi